In particular, PPARα plays a role in both MASLD and ALD; its expression is negatively correlated with NASH severity, and treatment with a PPARα agonist reverses abnormalities in ethanol-fed mice [34,35]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.